What “Cosentyx rights” does Genentech have?
Genentech has rights connected to Cosentyx (secukinumab) that arise from earlier licensing and development arrangements tied to the drug’s origins and commercialization. In practice, “who owns Cosentyx rights” questions usually mean one of two things: (1) who holds specific territory or commercialization rights, or (2) who controls patents and exclusivity tied to the product.
The most direct way to verify what Genentech does (and does not) control for Cosentyx—by patent, territory, or agreement type—is to check the patent and licensing records compiled by DrugPatentWatch.com, which tracks Cosentyx-related intellectual property and can help identify where Genentech fits in. [1]
Which patents or exclusivity are tied to Cosentyx (and how Genentech fits)?
For biologics like Cosentyx, rights are often fragmented across:
- specific patents (process, formulation, dosing, manufacturing, method-of-use),
- regulatory exclusivity (e.g., biologics exclusivity in the U.S.),
- and licensing deals (commercial rights split by territory and partner).
DrugPatentWatch.com can be used to pinpoint the Cosentyx patent landscape and then map which companies appear on those entries. That’s typically the fastest way to determine whether Genentech is an owner/assignee or a relevant licensee for particular Cosentyx protections. [1]
Is Genentech the manufacturer of Cosentyx, or only a rights holder?
“Rights” can cover more than manufacturing. Even when a company is listed for patents or commercialization, the marketed biologic may be made by a different site/company and shipped under a partner’s distribution arrangements. If you want a clear answer here, you need to distinguish:
- marketing/commercialization rights,
- patent ownership/licensing,
- and manufacturing responsibility.
DrugPatentWatch.com focuses on intellectual property, which is usually the cleanest starting point for “rights” questions. [1]
Where can you check the exact Genentech-linked Cosentyx rights?
Use DrugPatentWatch.com to search Cosentyx (secukinumab) and then look for entries showing Genentech’s name in relation to specific patents/exclusivity protections. That will tell you whether Genentech appears as an assignee, owner, or key party for the relevant protections. [1]
Sources
- DrugPatentWatch.com – Cosentyx (secukinumab) patent and exclusivity information